The Business Magazine - B2B Business News - Site Logo

Warning: Undefined array key "tbm_visit_edition_me" in /home/970822.cloudwaysapps.com/utkbfqnuhr/public_html/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 27
The Business Magazine - B2B Business News - Site Logo
The Business Magazine July 2024
Read now
PICK YOUR EDITION

Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic

The Business Magazine article image for: Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic
8 November 2022

Oxford-based Scancell Holdings, which develops  novel immunotherapies, has in-licensed the SNAPvax™ technology from Vaccitech plc, another Oxford biopharmaceutical company developing vaccines, and the team behind the Oxford AstraZeneca vaccine.

This agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a Phase 1 clinical study in cancer patients in 2024.

Modi-2 is the second product from Scancell's Moditope platform, which leverages the immune system to target a unique class of post-translational modifications (PTMs) upregulated by many cancers. The SNAPvax™ technology enables peptides to self-assemble with TLR-7/8a, a powerful adjuvant, to promote strong T cell responses and is proven to successfully overcome formulation issues associated with immunogenic peptide antigens, which are often highly hydrophobic and prone to manufacturing challenges with conventional formulations.

Prof Lindy Durrant, Chief Executive Officer, Scancell, said: "We are pleased to partner with Vaccitech to take the second candidate from our Moditope platform through GMP and subsequent clinical development. With its elegant and effective solution, the SNAPvax™ technology provides an excellent method for formulation of the Modi-2 vaccine. Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the hope that we can bring it into a Phase 1 clinical study during 2024."

Dr Geoffrey Lynn, Senior Vice President of Synthetic Platforms at Vaccitech commented: "We are delighted that Scancell has selected our SNAPvax™technology for the development of their Modi-2 product. SNAPvax™ was developed to overcome the challenges of formulating and delivering PTMs and ensure consistent formulations of any peptide antigens, for reliable T cell priming. Our team is therefore keen to support the development of this promising product with the hope that it will address immediate needs of cancer patients and more broadly highlight the promise of targeting PTMs."


Share 

Nicky Godding is editor of The Business Magazine. Before her journalism career, she worked mainly in public relations moving into writing when she was invited to launch Retail Watch, a publication covering retail and real estate across Europe.

After some years of constant travelling, she tucked away her passport and concentrated on business writing, co-founding a successful regional business magazine. She has interviewed some of the UK’s most successful entrepreneurs who have built multi-million-pound businesses and reported on many science and technology firsts.

She reports on the region’s thriving business economy from start-ups, family businesses and multi-million-pound corporations, to the professionals that support their growth and the institutions that educate the next generation of business leaders.

Latest deal ticket

All deals

Events

All events

Related news


Group Titles

Dorset BIZ NewsHampshire BIZ News
cross